The National Institutes of Health last week named five new directors to its advisory committee. They are David Botstein, Nancy Adler, Alexander Lerner, Christine Seidman, and Tadataka Yamada.
Botstein is the director of the Lewis-Sigler Institute of Integrative Genomics at Princeton University. He has developed methods to study budding yeast and the functions of the actin and tubulin cytoskeletons and has made theoretical contributions to the human genome linkage mapping. His current research focuses on yeast biology at the system level.
Adler is a professor of psychology at the University of California, San Francisco. She's a member of the Institute of Medicine of the National Academy of Sciences.
Lerner is CEO of the Illinois State Medical Society. He was formerly president of his own consulting firm.
Seidman is a professor in the departments of medicine and genetics at Harvard Medical School and Brigham and Women's Hospital. She is also an investigator at the Howard Hughes Medical Institute.
Yamada is a director and chairman of research and development at GlaxoSmithKline. He was formerly chairman of the department of internal medicine at the University of Michigan Medical School.
The National Institute of Allergy and Infectious Diseases last week named four new members to its principal advisory board. They are Barbara Baird, Kathryn Edwards, Martin Rosenberg, and Megan Sykes.
Baird is director of the nanotechnology center at Cornell University and principal investigator for Cornell's training grant in molecular biophysics.
Edwards is professor of pediatrics at Vanderbilt University and leads the NIAID-supported vaccine and treatment evaluation unit at Vanderbilt. She has served as an advisor to the Centers for Disease Control and Prevention and the Food and Drug Administration.
Rosenberg is chief scientific officer of Promega. He is a director at Promega, Cubist Pharmaceuticals, Medical College of Wisconsin Research Foundation, Nereus Pharmaceuticals, Anacor Pharmaceuticals, and Scarab Genomics.
Sykes is a professor of medicine at Harvard Medical School. She is an immunologist and associate director of the Transplantation Biology Research Center at Massachusetts General Hospital.
Donald Kaplan has retired as president and chief operating officer of Protein Polymer Technologies "to pursue other opportunities," the company said last week. Kaplan will continue to serve as a director and consultant.
Affymetrix said last week it had named Robert Trice to its board of directors.
Trice is senior vice president for business development at Lockheed Martin and chairman and CEO of Lockheed Martin Global. Prior to that, he was vice president and general manager for business development at McDonnell Douglas Aerospace.
John Hatsopoulos joined Viaspace as a director, the defense technology company said last week.
Hatsopoulos is CEO of American Distributed Generation and chairman of GlenRose Capital, a leveraged buyout investment fund. Previously, he was co-founder, vice chairman, president and chief financial officer of Thermo Electron.
CombiMatrix this week launched its 4X2K Influenza A Research Microarray on its CustomArray 4X2K platform. The microarray can detect and accurately type flu strains in fewer than four hours, at a cost per test of $99, the company said in a statement. The assay can identify H5N1 bird flu and provide information on the subtype of H5 influenzas while simultaneously identifying all other strains of Influenza A and providing a "rich amount of information on mutations and novel strains of flu not yet seen," the company said.
CombiMatrix offers the Influenza A assay as a tool or as a service. This system is also being developed as a field-deployable biodetector, to be available soon.
ReliaGene this week launched its Y-Screen Forensic DNA Purification Kit, the first comprehensive forensic DNA analysis system for the purification and detection of human male DNA in crime scene evidence samples, the company said in a statement.